Ask The Board
-
What Happens If We Have A Bunch Of COVID-19 Therapeutic And Vaccine Development Failures? Could Biopharma Be The Next Dot-Com Bubble To Burst In 2021?
1/4/2021
See the answer from Thomas Wiggans, the founder, chairman, and CEO of Dermira.
-
What COVID-19-Induced Trends Impacting Your Company’s Operations Do You Anticipate Continuing Well Beyond The End Of The Current Pandemic?
1/4/2021
See the answer from Jim Scibetta, CEO of Maverick Therapeutics.
-
Could The Pandemic Be Just What The Doctor Ordered For Bringing More R&D Minds To Major Biopharma Hubs (e.g., Boston, San Fran)?
1/4/2021
See the answer from Carol Nacy, PH.D., CEO of Sequella, Inc., a private company that develops new anti-infective drugs.
-
What — If Any — “Silver Linings” Have You Observed Take Place At Your Company Resulting From The Chaos Caused By COVID-19?
10/30/2020
See the answer from Tom DiLenge, president, advocacy, law & public policy division for the Biotechnology Innovation Organization (BIO).
-
What Was Your Biggest Business Learning From The First Half Of 2020 And Why?
10/30/2020
See the answer from Liz Bywater, Ph.D., speaker and author of Slow Down to Speed Up! who advises executives at some of the world’s most successful companies.
-
What Is Your Biggest Concern Regarding Biopharma’s Reputation With The American People If We Do Not Have A COVID-19 Vaccine By The End Of 2020?
10/30/2020
See the answer from Mitchell Katz, Ph.D., VP of development operations at Ferring Pharmaceuticals.
-
What Is Your Biggest Concern Regarding The Biopharma Industry’s Reputation With The American People If We Don’t Have A COVID-19 Vaccine By The End Of This Year?
10/1/2020
See the answer from Francois Nader, chairman of Acceleron Pharma.
-
What’s Your Perspective On The Rise Around Virtual Pitching To Investors, And What Will Be Its Impact On Annual Investor Meetings Like The Biotech Showcase And JPM In 2021?
10/1/2020
See the answer from Dennis Purcell, a founder and senior advisor of Aisling Capital.
-
What — If Any — Silver Linings Have You Observed Taking Place At Your Company Resulting From The Chaos Caused By COVID-19?
10/1/2020
See the answer from Joe Ferra, CFO of Syros Pharmaceuticals.
-
What Additional Protocols Have You Observed Being Implemented To Protect Biopharma Manufacturing Employees, And What Impact Do You Anticipate On The Bottom Line From These Added Costs?
9/1/2020
See the answer from Jacks Lee, a global pharmaceutical executive with 25+ years of experiences in vaccines, biopharmaceuticals, and small molecule pharmaceuticals.